The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Rigicon sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Rigicon is a medical equipment company that designs, manufactures, and markets urological devices. The company’s product portfolio includes inflatable penile prosthesis, malleable penile prosthesis, artificial urinary sphincter, testicular prosthesis, and surgical instruments. It offers products under the brands, Infla10, Rigi10, Conti, Testi10, and Rigicon. The company has presence across North America, EMEA, Latin America and Asia Pacific. Rigicon is headquartered in Ronkonkoma, New York, the US.
The key metrics of Rigicon related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Rigicon is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Rigicon.
For a detailed understanding of the performance of Rigicon, buy the report here.